Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan in HeartMate 3 LVAD recipients
NL-OMON52124Phase 4Completed
- Sponsor
- University of Zagreb School of Medicine
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in heart failure (HF) and heart failure with reduced ejection fraction (HFrEF) comparing Sacubitril/valsartan with Standard of care blood pressure treatment (2 arms). Primary endpoints: Primary safety endpoint, End-stage renal disease component and 3 more. Started Nov 2021; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)heart failure with reduced ejection fraction (HFrEF)
Beyond the preview
Go deeper on NL-OMON52124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52124.